Use of N-Acetylcysteine for Clozapine-Induced Acute Liver Injury: A Case Report and Literature Review

J Pharm Pract. 2023 Apr;36(2):463-467. doi: 10.1177/08971900211034007. Epub 2021 Jul 20.

Abstract

Purpose: To report a case of clozapine-induced hepatotoxicity managed with intravenous (IV) N-acetylcysteine (NAC) and summarize the available literature. Summary: A 46-year-old woman with history of bipolar disorder with psychotic features presented to the intensive care unit with asterixis and elevations in liver enzymes. The patient had been initiated on risperidone, clozapine, and lithium approximately 1 month prior to admission. After ruling out other possible non-drug etiologies, clozapine was suspected as the likeliest cause of the acute liver injury. Her acute liver injury was managed with the discontinuation of all antipsychotics, administration of IV NAC, and other standard of care supportive measures. Conclusion: Although clozapine has been associated with hepatitis and acute liver failure, there are no reports of NAC used in the management of clozapine-induced hepatotoxicity. NAC was used in our patient after considering the potential benefit and limited adverse effects. The role of NAC in non-acetaminophen-induced acute liver failure remains promising, but more research is warranted.

Keywords: acetylcysteine; clozapine; drug-induced liver injury.

Publication types

  • Review
  • Case Reports

MeSH terms

  • Acetylcysteine / therapeutic use
  • Chemical and Drug Induced Liver Injury* / diagnosis
  • Chemical and Drug Induced Liver Injury* / drug therapy
  • Chemical and Drug Induced Liver Injury* / etiology
  • Clozapine* / adverse effects
  • Drug-Related Side Effects and Adverse Reactions* / drug therapy
  • Female
  • Humans
  • Liver Failure, Acute* / drug therapy
  • Middle Aged

Substances

  • Acetylcysteine
  • Clozapine